British pharmaceutical giant AstraZeneca said Thursday it would invest $15 billion in China through 2030 to expand its medicines manufacturing and research, as UK Prime Minister Keir Starmer visits Beijing.
“China… has become a critical contributor to scientific innovation, advanced manufacturing, and global public health,” AstraZeneca chief executive Pascal Soriot said in a statement.
AstraZeneca has recently invested heavily in the United States, under pressure from President Donald Trump.
Add Comment